Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $10,267 | — | $14,000 | — |
| Operating expenses: | ||||
| Research and development | 30,994 | 34,664 | 57,807 | 59,719 |
| General and administrative | 10,963 | 10,454 | 22,096 | 20,296 |
| Total operating expenses | 41,957 | 45,118 | 79,903 | 80,015 |
| Loss from operations | (31,690) | (45,118) | (65,903) | (80,015) |
| Other income: | ||||
| Interest income | 9,718 | 11,260 | 19,570 | 22,649 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's G&A?
- Janux Therapeutics (JANX) reported G&A of $10.96M in Q2 2026.
- How has Janux Therapeutics's G&A changed year-over-year?
- Janux Therapeutics's G&A increased by 4.9% year-over-year, from $10.45M to $10.96M.
- What is the long-term trend for Janux Therapeutics's G&A?
- Over 4 years (2021 to 2025), Janux Therapeutics's G&A has grown at a 41.8% compound annual growth rate (CAGR), from $10.33M to $41.77M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Janux Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude